MedBodh Drug Regulation | Updated 22 October 2026. WHO has called for proposals from Member States interested in hosting the 20th International Conference of Drug Regulatory Authorities (ICDRA), expected toward the end of 2027. The announcement concerns international regulatory cooperation; it is not a new medicine approval, a recall or a change to Indian drug law.
Quick note sheet
- Event: 20th ICDRA.
- Expected period: late 2027.
- Call issued: October 2026.
- Initial expression-of-interest date: 20 November 2026.
- Eligible respondents: interested WHO Member States through appropriate channels.
- Indian context: CDSCO rules remain unchanged by this announcement.
What is ICDRA?
ICDRA is an international forum that convenes medicine regulators and related stakeholders to discuss common challenges in assuring the quality, safety and effectiveness of medical products. Dialogue can help regulators share experience, identify gaps and consider ways to cooperate, while national legal responsibilities remain with each country’s authorities.
Regulatory themes to watch
| Theme | Why it matters |
|---|---|
| Regulatory convergence | Shared technical approaches can reduce unnecessary duplication |
| Regulatory reliance | Use of trusted assessments within national legal frameworks |
| Pharmacovigilance | Detection and communication of suspected adverse reactions |
| Medical-product quality | Supply-chain and manufacturing oversight |
| Innovation and digital systems | New evaluation tools and data systems |
| Emergency preparedness | Coordinated response to urgent public-health needs |
What the hosting invitation means
WHO encourages interested Member States to submit an initial expression of interest by 20 November 2026. This should not be mistaken for a general deadline for doctors, pharmacists or students to register for the 2027 event. Final hosting arrangements and programme details should be checked against later WHO notices.
Implications for India
International regulatory discussion is relevant to CDSCO, the Indian Pharmacopoeia Commission, manufacturers, pharmacovigilance professionals and public-health programmes. However, international conference themes do not themselves amend the Drugs and Cosmetics Act or Rules, authorise a medicine or replace national safety alerts.
Practical pharmacovigilance checklist
- Recognise suspected adverse drug reactions, including serious or unexpected reactions.
- Record suspected medicine, batch details where available, timing and clinical course.
- Report through the appropriate Indian pharmacovigilance channels.
- Verify product recalls and safety alerts against official CDSCO/IPC communications.
- Avoid presenting preliminary international discussions as binding Indian regulation.
Frequently asked questions
Is ICDRA a drug-approval body?
No. Individual national authorities retain their legal approval responsibilities.
Has WHO changed Indian drug rules?
No. This announcement concerns proposals to host a future conference.
Can an individual clinician apply to host ICDRA?
The announcement addresses interested Member States through official channels.
Official source
WHO: Call for proposals to host the 20th ICDRA.
Regulatory interpretation is for education; refer to WHO and Indian regulators for current binding requirements.